Diamond Equity Equities Analysts Cut Earnings Estimates for ProPhase Labs, Inc. (NASDAQ:PRPH)

ProPhase Labs, Inc. (NASDAQ:PRPH) – Stock analysts at Diamond Equity dropped their Q1 2024 EPS estimates for ProPhase Labs in a note issued to investors on Monday, April 22nd. Diamond Equity analyst H. Diamond now forecasts that the company will post earnings per share of ($0.15) for the quarter, down from their previous estimate of ($0.11). The consensus estimate for ProPhase Labs’ current full-year earnings is ($0.88) per share. Diamond Equity also issued estimates for ProPhase Labs’ Q2 2024 earnings at ($0.08) EPS, Q3 2024 earnings at $0.04 EPS, Q4 2024 earnings at $0.09 EPS, FY2024 earnings at ($0.10) EPS and FY2025 earnings at $0.48 EPS.

Separately, HC Wainwright restated a “buy” rating and set a $11.00 price target on shares of ProPhase Labs in a research report on Wednesday, February 21st.

ProPhase Labs Trading Down 1.9 %

PRPH stock opened at $5.06 on Thursday. The company has a debt-to-equity ratio of 0.29, a quick ratio of 2.10 and a current ratio of 2.28. The firm’s fifty day moving average is $5.54 and its 200 day moving average is $5.00. ProPhase Labs has a one year low of $4.05 and a one year high of $9.94.

ProPhase Labs (NASDAQ:PRPH) last released its quarterly earnings results on Thursday, March 28th. The company reported ($0.51) EPS for the quarter. The firm had revenue of $3.50 million for the quarter, compared to analyst estimates of $10.71 million. ProPhase Labs had a negative net margin of 37.81% and a negative return on equity of 29.83%.

Hedge Funds Weigh In On ProPhase Labs

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. HighTower Advisors LLC purchased a new position in ProPhase Labs during the third quarter valued at $756,000. SVB Wealth LLC purchased a new position in ProPhase Labs during the third quarter valued at $208,000. Finally, Tower Research Capital LLC TRC lifted its stake in shares of ProPhase Labs by 50.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 15,010 shares of the company’s stock worth $68,000 after buying an additional 5,026 shares in the last quarter. 9.45% of the stock is owned by hedge funds and other institutional investors.

About ProPhase Labs

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.